

## Publication auxquelles l'Aretasc à participe 2015

- 1- interest of short androgen deprivation therapy (ADT) combined with radiotherapy (RT) as salvage for biological relapse (BR) after radical prostatectomy (RP) results of GetuG-AFU 16 phase III randomized trial : asco 2015 abst 5006.
- 2 – Pepita Etude prospective de cohorte évaluant l'efficacité et la tolérance d'un traitement de 2ed ligne par Tarceva chez de patients atteints d'un cancer bronchique non à petites cellules(CBNPC) de type épidermoïde avancé ou métastatique :Janvier-Février 2015 : 19 congres de pneumologie française.
- 3 - Erlotinib in 2<sup>nd</sup> line in advanced squamous :N abstract WCLC 2015 (total 490 words for 500 words allowed SCLS :Final results of the PEPITA cohort :A.Vergnenègre,O.Molinier, I.Monnet, Paris-France.
- 4- Epidermal growth factor receptor (EGFR) pathway biomarkers in the randomized Phase III trial of Erlotinib versus Observation in Ovarian cancer patients with no evidence of disease progression after first-line platinum-based chemotherapy. Despierre E, Vergote I, Anderson R. Targeted Oncology :Dec 2015, volume 10,issue 4.
- 5 – Final Analysis :Ten year follow-up of BCIRG 006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AT> T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC >TH) with docetaxel, carboplatin and trastuzumab TCH) in HER2+ early breast cancer.  
Slamon D, EiermannW, Robert N, Giermek J, on behalf of the BCIRG – 006 investigators SABC 8-12 Decembre 2015.
- 6- Multicentre randomised phase II trial of gemcitabine+ platinum, with or without trastuzumab in advanced or metastatic urothelial carcinoma overexpressing HER2.  
Eur J Cancer 2015 Jan 15 ; 51(1)45-54  
S.Oudart,S.Culine, Y.Vano
- 7- Minimal impact of adjuvant exemstane or tamoxifen treatment on mammographic breast density in postmenospausal breast cancer patients : a Dutch TEAM trial analysis.  
Acta Oncol, 2015 Mar ;54(3) :349-60